Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Reishi-soppekstrakt for tretthet og/eller artralgi/myalgi hos pasienter med brystkreft på aromatasehemmere

2. november 2026 oppdatert av: Mayo Clinic

Reishi-soppekstrakt for tretthet og/eller artralgi hos pasienter med brystkreft på aromatasehemmere: en randomisert fase II MNCCTN-studie

This phase II trial tests how well Reishi mushroom extract works in treating fatigue and/or joint/muscle pain (arthralgias/myalgias) in patients with breast cancer on aromatase inhibitors. Fatigue and arthralgias/myalgias are common symptoms in breast cancer patients taking aromatase inhibitors (AI). Given the long duration of AI treatment for some women (up to 10 years), these symptoms can significantly impact quality of life and premature discontinuation of AIs, a beneficial medication. Reishi mushrooms are among several medicinal mushrooms that have been used for hundreds of years, mainly in Asian countries, to help enhance the immune system, reduce stress, improve sleep, and lessen fatigue. Reishi mushroom extracts have not been studied explicitly for treatment-induced arthralgias/myalgias, but have been shown to improve quality of life, muscular strength, pain, and flexibility. Information from this study may help researchers determine the effect of Reishi mushroom extract on fatigue and arthralgias/myalgias in breast cancer patients receiving an AI.

Studieoversikt

Detaljert beskrivelse

PRIMARY OBJECTIVE:

I. To evaluate the efficacy of 1,000 mg three times daily (TID) of Reishi mushroom extracts as therapy for cancer-related fatigue measured by uniscale measurement at the end of four weeks.

SECONDARY OBJECTIVES:

I. To evaluate the efficacy of Reishi mushroom extracts as therapy for cancer-related arthralgias at the end of four weeks and four weeks after cross-over as measured by the Brief Pain index (BPI)-adapted for AI associated arthralgias.

II. To evaluate the effect of Reishi mushroom extracts on cancer-related quality of life (QOL), as measured by uniscale, at the end of four weeks and four weeks after cross-over.

III. To evaluate the efficacy of Reishi mushroom extracts on mood, as assessed by the World Health Organization Five Well-Being Index (WHO-5) item well-being scale, at the end of four weeks and four weeks after cross-over.

IV. To evaluate treatment toxicity between the two treatment arms, as measured by a patient symptom experience diary and weekly calls from the study team.

V. To evaluate the interest, knowledge, and acceptance of integrative treatments for cancer-related symptoms.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive Reishi mushroom extract orally (PO) TID on days 1-28 for weeks 1-4 and then placebo PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive placebo PO TID on days 1-28 for weeks 1-4 and Reishi mushroom extract PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days.

Studietype

Intervensjonell

Registrering (Antatt)

80

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Minnesota
      • Albert Lea, Minnesota, Forente stater, 56007
        • Aktiv, ikke rekrutterende
        • Mayo Clinic Health System in Albert Lea
      • Baxter, Minnesota, Forente stater, 56425
        • Aktiv, ikke rekrutterende
        • Essentia Health Baxter Clinic
      • Bemidji, Minnesota, Forente stater, 56601
        • Aktiv, ikke rekrutterende
        • Sanford Joe Lueken Cancer Center
      • Brainerd, Minnesota, Forente stater, 56401
        • Aktiv, ikke rekrutterende
        • Essentia Health Saint Joseph's Medical Center
      • Deer River, Minnesota, Forente stater, 56636
        • Aktiv, ikke rekrutterende
        • Essentia Health Deer River Clinic
      • Detroit Lakes, Minnesota, Forente stater, 56501
        • Aktiv, ikke rekrutterende
        • Essentia Health Saint Mary's - Detroit Lakes Clinic
      • Duluth, Minnesota, Forente stater, 55805
        • Aktiv, ikke rekrutterende
        • Essentia Health Cancer Center
      • Ely, Minnesota, Forente stater, 55731
        • Aktiv, ikke rekrutterende
        • Essentia Health Ely Clinic
      • Fosston, Minnesota, Forente stater, 56542
        • Aktiv, ikke rekrutterende
        • Essentia Health Fosston
      • Grand Rapids, Minnesota, Forente stater, 55744
        • Aktiv, ikke rekrutterende
        • Fairview Grand Itasca Clinic & Hospital
      • Hibbing, Minnesota, Forente stater, 55746
        • Aktiv, ikke rekrutterende
        • Essentia Health Hibbing Clinic
      • Hibbing, Minnesota, Forente stater, 55746
        • Aktiv, ikke rekrutterende
        • Fairview Range Medical Center
      • International Falls, Minnesota, Forente stater, 56649
        • Aktiv, ikke rekrutterende
        • Essentia Health International Falls Clinic
      • Mankato, Minnesota, Forente stater, 56001
        • Aktiv, ikke rekrutterende
        • Mayo Clinic Health Systems-Mankato
      • Monticello, Minnesota, Forente stater, 55362
        • Tilbaketrukket
        • MMCORC CentraCare Monticello Cancer Center
      • Moose Lake, Minnesota, Forente stater, 55767
        • Aktiv, ikke rekrutterende
        • Essentia Health Moose Lake
      • Park Rapids, Minnesota, Forente stater, 56470
        • Aktiv, ikke rekrutterende
        • Essentia Health Park Rapids
      • Princeton, Minnesota, Forente stater, 55731
        • Aktiv, ikke rekrutterende
        • Fairview Northland Medical Center
      • Rochester, Minnesota, Forente stater, 55905
        • Rekruttering
        • Mayo Clinic in Rochester
        • Hovedetterforsker:
          • Stacy D. D'Andre, M.D.
        • Ta kontakt med:
      • Sandstone, Minnesota, Forente stater, 55072
        • Aktiv, ikke rekrutterende
        • Essentia Health Sandstone
      • Thief River Falls, Minnesota, Forente stater, 56701
        • Aktiv, ikke rekrutterende
        • Sanford Thief River Falls Medical Center
      • Virginia, Minnesota, Forente stater, 55792
        • Aktiv, ikke rekrutterende
        • Essentia Health Virginia Clinic
      • Worthington, Minnesota, Forente stater, 56187
        • Aktiv, ikke rekrutterende
        • Sanford Worthington Medical Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18 years
  • History of breast cancer, estrogen receptor positive (ER+), Her 2 positive or negative
  • Fatigue ≥ 4/10
  • Currently post-menopausal (as defined by National Comprehensive Cancer Network (version 4.2024), taking any aromatase inhibitor in the curative setting and planning to be on such for at least 8 weeks after registration. [Patients on concurrent ovarian suppression (such as with leuprolide acetate, goserelin) are allowed]; CDK 4/6 inhibitors abemaciclib, ribociclib ARE allowed
  • Prior treatment: last chemotherapy ≥ 90 days prior to randomization (if treated with chemotherapy)
  • On a stable dose of pain medications if pain medications are being regularly used. (i.e., no change in dosage in the past 30 days)
  • If on supplements, must be on stable dose with no plan to change; not on or planning any acupuncture or other specific supportive modalities for fatigue or AI arthralgias
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
  • White blood cell count (WBC) ≥ 3,000/mm^3 (obtained ≤ 30 days prior to randomization)
  • Hemoglobin ≥ 10 g/dL (obtained ≤ 30 days prior to randomization)
  • Platelet count ≥ 100,000/mm^3 (obtained ≤ 30 days prior to randomization)
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 30 days prior to randomization)
  • Alanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 1.2 x ULN (obtained ≤ 30 days prior to randomization)
  • Prothrombin time (PT)/activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN (obtained ≤ 30 days prior to randomization)
  • Negative pregnancy test done ≤ 7 days prior to registration, for persons on concurrent ovarian suppression only
  • Provide informed consent
  • Ability to complete questionnaires
  • Willing to return to enrolling institution during the active monitoring phase of the study
  • Patients who have had a recent surgery or procedure should be healed and cleared by their clinician and/or surgeon per local standards, prior to registration

Exclusion Criteria:

  • Other known uncontrolled medical conditions causing fatigue such as untreated thyroid disease, depression, fibromyalgia, chronic fatigue syndrome, infection, autoimmune disease, or active/untreated hepatitis

  • Allergy to mushrooms

  • On anticoagulation medication or aspirin or having a known bleeding disorder

  • On any specific medication for fatigue (e.g., methylphenidate)

  • Metastatic cancer diagnosis (history of nodal metastases is allowed)

  • Chronic steroid use, unless on physiologic replacement doses

  • Current use of any medical mushrooms

  • On medications for diabetes

  • History of symptomatic hypotension

  • Taking CYP3A4, CYP2D6 sensitive substrates which can be located at the following link: https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems

  • Drugs which exhibit either >20% inhibition or >20% induction of CYP2E1 in vivo, such as: Acetaminophen, Dapsone, Enflurane, Halothane, Isoflurane, & Theophylline

  • Taking olaparib

  • Any of the following because this study involves an agent that has unknown genotoxic, mutagenic and teratogenic effects:

    • Pregnant persons
    • Nursing persons
    • Persons on concurrent ovarian suppression who are unwilling to employ adequate contraception (e.g., hormonal methods, barrier methods, intrauterine device, abstinence)
  • Planned surgery or procedure during time on study and ≤ 14 days after last dose, due to bleeding risks

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm I (Reishi mushroom extract, placebo)

Patients receive Reishi mushroom extract PO TID on days 1-28 for weeks 1-4 and then placebo PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity.

Ancillary studies

Andre navn:
  • Livskvalitetsvurdering

Ancillary studies

Given PO

Given Reishi mushroom extract PO

Andre navn:
  • Agaricus bisporus ekstrakt
  • Dyrket sopp
Eksperimentell: Arm II (placebo, Reishi mushroom extract)

Patients receive placebo PO TID on days 1-28 for weeks 1-4 and Reishi mushroom extract PO TID on days 1-28 for weeks 5-8 in the absence of disease progression or unacceptable toxicity.

Ancillary studies

Andre navn:
  • Livskvalitetsvurdering

Ancillary studies

Given PO

Given Reishi mushroom extract PO

Andre navn:
  • Agaricus bisporus ekstrakt
  • Dyrket sopp

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in fatigue scores
Tidsramme: Baseline to end of four weeks

Based on a single item fatigue uniscale question. Will be compared between arms using a two-sided two-sample t-test assuming equal variances in each group.

Baseline to end of four weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in quality of life
Tidsramme: Baseline to the end of four weeks and four weeks after cross-over

Measured by the World Health Organization-Five Well-Being Index. Will be compared between arms using two-sample, two-sided t-tests assuming equal variances and alpha levels of 5%. The analyses of the crossover portion of the study will be descriptive. Mean values will be plotted over time by arm. A formal crossover analysis will also be performed using Senn's linear modeling approach.

Baseline to the end of four weeks and four weeks after cross-over
Change in arthralgias
Tidsramme: Baseline to the end of four weeks and four weeks after cross-over

Measured by the Brief Pain Inventory for Aromatase Inhibitor Induced Arthralgia. Will be compared between arms using two-sample, two-sided t-tests assuming equal variances and alpha levels of 5%. The analyses of the crossover portion of the study will be descriptive. Mean values will be plotted over time by arm. A formal crossover analysis will also be performed using Senn's linear modeling approach.

Baseline to the end of four weeks and four weeks after cross-over
Incidence of adverse events
Tidsramme: Up to 30 days follow-up

Measured by the symptom experience diary. Will be compared between arms using two-sample, two-sided t-tests assuming equal variances and alpha levels of 5%. The analyses of the crossover portion of the study will be descriptive. Mean values will be plotted over time by arm. A formal crossover analysis will also be performed using Senn's linear modeling approach.

Up to 30 days follow-up

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Stacy D. D'Andre, MD, Mayo Clinic in Rochester

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

18. oktober 2023

Primær fullføring (Antatt)

15. mai 2029

Studiet fullført (Antatt)

15. juni 2029

Datoer for studieregistrering

Først innsendt

31. august 2023

Først innsendt som oppfylte QC-kriteriene

31. august 2023

Først lagt ut (Faktiske)

7. september 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • MC221002
  • MC221002 (Annen identifikator: Mayo Clinic in Rochester)
  • NCI-2023-06578 (Registeridentifikator: CTRP (Clinical Trials Reporting Program))
  • 23-005266 (Annen identifikator: Mayo Clinic Institutional Review Board)
  • MNCCTN032 (Annen identifikator: Minnesota Cancer Clinical Trials Network)

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere